Cytomx Prices IPO Below Range As More Biotechs Scale Down
Cancer-focused biotech Cytomx Therapeutics Inc. priced an $80 million initial public offering below range Thursday, the second venture-backed life science company this week to price an IPO lower than expected, marking...To view the full article, register now.
Already a subscriber? Click here to view full article